|
|
|
|
| | |
| | |
|
|
|
|
| | |
| |
 |
|
 |
|
|
|
| Sakata-Takatani,
K., Matsuo, N., Sumiyoshi, H., Tsuda, T., Yoshioka, H.: Identification
of a functional CCAAT-like motif in the core promoter of the mouse
pro-α1(V) collagen gene (Col5a1). Matrix Biol. 23, 87-99, 2004 |  |
|
|
| Kimoto,
K., Nakatsuka, K., Matsuo, N., Yoshioka, H.: p38 MAPK mediates the
expression of type I collagen induced by TGF-b2 in human retinal
pigment epithelial cells ARPE-19. Invest. Ophthalmol. Vis. Sci. 45,
2431-2437, 2004 | | | | | Sumiyoshi,
H., Mor, N., Lee, S. Y., Doty, S., Henderson, S., Tanaka, S., Yoshioka,
H., Rattan, S., Ramirez, F.: Esophageal muscle physiology and
morphogenesis require assembly of a collagen XIX-rich basement membrane
zone. J. Cell Biol. 166, 591-600, 2004 | | | | | Nagato,
H., Matsuo, N., Sumiyoshi, H., Sakata-Takatani, K., Nasu, M., Yoshioka,
H.: The Transcription factor CCAAT-binding factor CBF/NF-Y and two
repressors regulate the core promoter of the human pro-α3(V) collagen gene (COL5A3). J. Biol. Chem. 279, 46373-46383, 2004 | | | | | Li,
Q., Shirabe, K., Kuwada, J. Y.:Chemokine signalingregulates sensory
cell migration in zebrafish. Dev. Biol. 269, 123-136, 2004 | | | | | Mieno,
H., Kuroda, K., Shinkai, H., Yoshioka, H., Tajima, S.: Type II collagen
accumulation in overlying dermo-epidermal junction of pilomatricoma is
mediated by bone morphogenetic protein 2 and 4. J. Invest. Dermatol.
122, 878-884, 2004 | | | | | Ishii
S., Yoshioka, H., Mannen, K., Kulkarni, A. B., Fan J.-Q.: Transgenic
mouse expressing human mutant a-galactosidase A in an endogenous enzyme
deficient background: a biochemical animal model for studying
active-site specific chaperone therapy for Fabry disease. Biochem.
Biophys. Acta 1690, 250-257, 2004 | | | | | Bando,
S., Takano, T., Yubisui, T., Shirabe, K., Takeshita, M., Nakagawa, A.:
Structure of human erythrocyte NADH-cytochrome b5 reductase. Acta
Crystalloqr D Biol. Crystalloqr 60, 1929-1934, 2004 | | | | | 調恒明：NADH-シトクロムb5還元酵素の遺伝生化学 血液・尿化学検査、免疫学的検査 日本臨床62 増刊号12 P765－767 2004年 |
|
|
|
|
| | |
|
| | |
|
| | |
| | | |
| | | |
 | | |
|
|
|
|
| | |
|
